Centennial of the Communist Party of China (11)
Release time:
2021-08-02
1971
9# April 13 , Lin Biao and others fled to the country and died in a plane crash near Wendur Khan in the Mongolian People's Republic. The fall of Lin Biao's counter-revolutionary group objectively declared the failure of "Cultural Revolution " theory and practice.
10March 25 , the 26th UN General Assembly passed Resolution 2758 by an overwhelming majority, restoring all legal rights of the People's Republic of China in the UN and immediately expelling Chiang Kai-shek's "Representative " from the UN and all its subordinate agencies.
19722
July 21 -28 , US President Nixon visited China. 28 , China and the United States issued a "Joint Communiqué" in Shanghai, marking the beginning of the normalization of relations between the two countries.
9June 25 -30 , Japanese Prime Minister Tanaka Kakuei was invited to visit China to negotiate and resolve the normalization of Sino-Japanese diplomatic relations. 29 , the Chinese and Japanese governments issued a "Joint Statement" announcing the establishment of diplomatic relations from now on.
19733
August 29 , according to Mao Zedong's opinion, Zhou Enlai presided over the meeting of the political bureau of the central Committee and decided that Deng Xiaoping would formally participate in the work of the state Council's business group and participate in foreign affairs activities as vice premier of the state Council.
8March 5 -20 , the State Council held the first national environmental protection conference and formulated "Several Provisions on Protecting and Improving the Environment (Trial Draft)". This is China's first comprehensive law on environmental protection.
19741
March 19 -20 , the Chinese People's Liberation Army was ordered to fight back in self-defense against the armed attack of the Saigon authorities in South Vietnam and successfully defended the territory of the Paracel Islands.
19751
March 5 , Deng Xiaoping was appointed Vice Chairman of the Central Military Commission.
1August 8 -10 , the second plenary session of the 10th CPC central Committee was held and Deng Xiaoping was elected vice chairman of the CPC central Committee.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31